Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review

Gynecological cancers are a major burden of disease for a significant group of women [1,2]. Disease recurrence is common and platinum resistance is a notable issue for these patients. For example, a substantial group of ovarian cancer (OC) patients have disease recurrence within six months after completion of first line platinum-based chemotherapy [3]. Moreover, durable responses to second line treatments are scarce, although a subset of patients with BRCA1/2-mutated ovarian cancer benefit from PARP-inhibitor treatment [4] and a subgroup of patients with cervical cancer and high PD-L1 expression benefit from immunotherapy with checkpoint inhibition [5].

Source: Cancer Treatment Reviews - March 2, 2023 Category: Cancer & Oncology Authors: Tim Schutte, Alaa Embaby, Neeltje Steeghs, Stevie van der Mierden, Willemien van Driel, Martin Rijlaarsdam, Alwin Huitema, Frans Opdam Tags: Anti-tumour Treatment Source Type: research